| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
856,317 |
| 52
Week Range: |
$206.39 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
19,405 |
420,533 |
| Total Sell Value |
$0 |
$0 |
$4,136,219 |
$77,127,618 |
| Total People Sold |
0 |
0 |
2 |
8 |
| Total Sell Transactions |
0 |
0 |
2 |
58 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dobmeier Eric |
Chief Operating Officer |
• – – |
2015-05-08 |
4 |
S |
$40.38 |
$689,380 |
D/D |
(17,074) |
82,777 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-05-07 |
4 |
B |
$37.07 |
$1,772,790 |
I/I |
47,717 |
26,040,800 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-05-06 |
4 |
B |
$35.85 |
$16,530,995 |
I/I |
453,995 |
25,993,083 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-05-05 |
4 |
B |
$33.99 |
$18,419,925 |
I/I |
530,952 |
25,539,088 |
2.25 |
- |
|
| Gryska David W |
Director |
– • – |
2015-04-08 |
4 |
OE |
$8.38 |
$41,900 |
D/D |
5,000 |
30,250 |
|
- |
|
| Cline Darren S |
SVP, Commercial |
• – – |
2015-03-13 |
4 |
S |
$38.65 |
$289,876 |
D/D |
(7,500) |
33,135 |
|
- |
|
| Himes Vaughn B |
EVP, Proc Svcs & Tech Ops |
• – – |
2015-03-12 |
4 |
S |
$36.65 |
$732,992 |
D/D |
(20,000) |
67,209 |
|
- |
|
| Himes Vaughn B |
EVP, Proc Svcs & Tech Ops |
• – – |
2015-03-12 |
4 |
OE |
$9.23 |
$184,600 |
D/D |
20,000 |
87,209 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-03-10 |
4 |
B |
$34.47 |
$321,921 |
I/I |
9,319 |
25,008,136 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-03-09 |
4 |
B |
$34.62 |
$9,556,609 |
I/I |
275,717 |
24,998,817 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-03-04 |
4 |
B |
$34.79 |
$822,418 |
I/I |
23,621 |
24,723,100 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-03-03 |
4 |
B |
$34.76 |
$14,814,701 |
I/I |
425,220 |
24,699,479 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-02-25 |
4 |
B |
$34.46 |
$2,194,758 |
I/I |
63,650 |
24,274,259 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-02-24 |
4 |
B |
$33.60 |
$7,341,491 |
I/I |
217,465 |
24,210,609 |
2.25 |
- |
|
| Cline Darren S |
SVP, CommercialOfficer |
• – – |
2015-02-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
40,635 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2015-01-06 |
4 |
AS |
$31.80 |
$534,320 |
D/D |
(16,804) |
559,710 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2015-01-06 |
4 |
OE |
$5.92 |
$99,480 |
D/D |
16,804 |
576,514 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2014-12-16 |
4 |
B |
$30.80 |
$60,997,873 |
I/I |
1,909,979 |
23,993,144 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2014-12-15 |
4 |
B |
$31.41 |
$30,861,290 |
I/I |
973,399 |
22,083,165 |
2.25 |
- |
|
| 14159, L.p. |
Director |
– • • |
2014-12-10 |
4 |
B |
$34.27 |
$22,501,700 |
I/I |
654,150 |
21,109,766 |
2.25 |
- |
|
| Fbb3 Llc |
Director |
– • • |
2014-12-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,678 |
|
- |
|
| 14159, L.p. |
Director |
– • • |
2014-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
61,014 |
107,504 |
|
- |
|
| 14159, L.p. |
Director |
– • • |
2014-12-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(399,208) |
0 |
|
- |
|
| 14159, L.p. |
Director |
– • • |
2014-12-09 |
4 |
B |
$33.28 |
$4,387,345 |
I/I |
128,430 |
20,455,616 |
2.25 |
- |
|
| 14159, L.p. |
Director |
– • • |
2014-12-08 |
4 |
B |
$32.56 |
$15,320,685 |
I/I |
465,316 |
20,327,186 |
2.25 |
- |
|
1805 Records found
|
|
Page 36 of 73 |
|
|
